Mapping the integration of social and ethical issues in health technology assessment

Lehoux, Pascale; Williams‐Jones, Bryn

doi:10.1017/s0266462307051513

Cited by 93 publications

(116 citation statements)

References 35 publications

(40 reference statements)

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…There are three general approaches to addressing the ethical justification and stakeholder assessment of germline genome editing: conducting primary research; conducting secondary analyses of published literature on the perceptions, acceptability, quality of life, attitudes, or values of stakeholders; and commissioning an expert review. 48,49 Surveys of the general public 41 and various scientific and health professional groups on their views toward genome editing have already begun (Alyssa Armsby et al, unpublished data; A.V. et al, unpublished data), but it is difficult to assess the impact of these attitudes in a population that has limited understanding of the technologies they are evaluating, as well as their generalizability to other populations and societies.…”

Section: Ethical Issues Related To the Success Of Human Germline Genomentioning

confidence: 99%

Human Germline Genome Editing

Ormond

Mortlock

Scholes

et al. 2017

The American Journal of Human Genetics

182

115

View full text Add to dashboard Cite

Section: Ethical Issues Related To the Success Of Human Germline Genomentioning

confidence: 99%

Human Germline Genome Editing

Ormond

Mortlock

Scholes

et al. 2017

The American Journal of Human Genetics

182

115

View full text Add to dashboard Cite

“…In order for policy makers to make decisions on how to strategically subsidize and encourage the broad distribution of promising technologies, they must be provided with detailed information concerning utility, benefits and risks prior to the technology's commercialization. (32) Regulatory risk assessments fail in this regard for they focus exclusively on risks, while the identification of obvious (i.e., economic) benefits are passively assessed after the commercialization of crop varieties. Furthermore, certain weaknesses are observable only after the GM crop has been cultivated within a 'real-world' setting.…”

Section: B Inclusion Of Farmers In the Assessment Of Gm-cropsmentioning

confidence: 99%

“…A better strategy for technology assessment and eventual adoption is to base decisions on more well rounded perceptions of potential social benefit that include social and ethical considerations. (32) Yet in relation to GM crops, which societal group is best suited to address and define the benefits, risks, and the socio-ethical concerns associated with this technology? Obviously, consumers and environmental interest groups are important stakeholders, and they have been key vocal participants in discussions about and analyses of GM crops.…”

Section: B Inclusion Of Farmers In the Assessment Of Gm-cropsmentioning

confidence: 99%

“…Including farmers as key stakeholders in pre-commercialization technology assessments -similar to what has been suggested for improving health technology assessment (37,38) -may be an effective means to identify the obvious benefits of an innovation, as well as the non-obvious benefits and potential risks that farmers should expect from the introduction of novel GM-crop varieties. Nonetheless, it is important to also consider ethical principles and specific challenges associated with such a process.…”

Section: Ethical Principles and Challenges With Farmer Participatimentioning

confidence: 99%

See 1 more Smart Citation

Principles for Incorporating Farmers in the Ethical Assessment of Genetically Modified Crops

Behrmann

Williams‐Jones

2010

Ethics Biology Eng Med

Self Cite

View full text Add to dashboard Cite

A current advance within the agricultural industry is the use of genetic engineering to produce novel crops for food production. This technology raises questions about how societies should position themselves with respect to genetically modified (GM) crop development and implementation; namely, how should the potentials and risks of this technology be evaluated? We argue that current methods to evaluate the risks and benefits of GM crops are inadequate and not conducive to the strategic development of this technology, where a way to ameliorate technology assessments for GM crops is to include farmers in the research process of evaluating these crops prior to their commercialization. However, particularities concerning the ethical status of such research require special consideration and vigilance. For example, in such technology assessment initiatives, farmers would occupy both the roles of research participant and research investigator. Other particularities surface due to factors related to the nature of GM crops. These particularities are examined with reference to concepts drawn from the field of research ethics, namely informed consent, compensatory decisions, and issues of participant inclusion/exclusion.

show abstract

“…However, these elements have not been sufficiently incorporated in practice, mainly due to restrictions in time and other resources (13). Several important initiatives emerged in recent years, going beyond the general consideration of sociocultural elements to explicitly address equity issues related to HTA.…”

mentioning

confidence: 99%

Considering Equity in Health Technology Assessment: An Exploratory Analysis of Agency Practices

Panteli¹,

Kreis

Busse³

2015

Int J Technol Assess Health Care

View full text Add to dashboard Cite

Objectives: Equity is one of the founding principles in most healthcare systems. Financial constraints entail an increased risk of exacerbating inequities and a greater need for evidence-based decisions. It is, therefore, both important and timely to enquire how equity can be addressed in health technology assessment (HTA) practice. We aimed to explore related practices from a broad range of HTA agencies, identify exemplary approaches and common concerns, and offer insights for future considerations. Methods: HTA agencies for which both methodological guides and HTA reports were publicly available were selected from an initial comprehensive pool. Information was extracted on issues ranging from a general commitment to fairness to specific measures targeting both methodological and process-related elements. Results: Methodological documents and ninety-eight reports from nineteen agencies were analyzed. Our findings indicate that equity was not a standard consideration in HTA report production. The nature of specific approaches and the amount of resources invested into including an equity perspective varied considerably. Specific measures (e.g., appropriate information sources, analytical tools, and schemes) were mentioned by almost half of the agencies analyzed. Albeit sporadic, both horizontal and vertical equity considerations were identified in included HTA reports. Conclusions: While varying legal contexts and institutional principles can lead to different interpretations of equity at the decision point, a combination of methodological and process-related practices could contribute to more equity-sensitive evaluations, especially in conjunction with enhanced dissemination of existing methodological tools. Networking initiatives on behalf of existing collaborating platforms could play an important role in this direction.

show abstract

Mapping the integration of social and ethical issues in health technology assessment

Cited by 93 publications

References 35 publications

Human Germline Genome Editing

Human Germline Genome Editing

Principles for Incorporating Farmers in the Ethical Assessment of Genetically Modified Crops

Considering Equity in Health Technology Assessment: An Exploratory Analysis of Agency Practices

Contact Info

Product

Resources

About